Arrowstreet Capital’s Altimmune ALT Stock Holding History

Arrowstreet Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-15,000	Closed	-$198K	–	2261
2020 Q3	$198K	Buy	+15,000	New	+$300K	﹤0.01%	2203
2018 Q1	–	Sell	-1,786	Closed	-$107K	–	1103
2017 Q4	$107K	Sell	1,786 -375	-17%	-$24K	﹤0.01%	1204
2017 Q3	$150K	Sell	2,161 -250	-10%	-$18.6K	﹤0.01%	1064
2017 Q2	$231K	Buy	2,411 +235	+11%	+$39.1K	﹤0.01%	982
2017 Q1	$530K	Buy	+2,176	New	+$1.16M	﹤0.01%	1081

Other funds holding ALT

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arrowstreet Capital's ALT Position: Q4 2020 in Review

Arrowstreet Capital sold out of Altimmune (ALT) in Q4 2020, closing a stake of 15,000 shares — an estimated $198K sold.

Arrowstreet Capital first reported a position in ALT in Q1 2017 and held it in 5 quarters. The position peaked at $530K in Q1 2017. 89 funds tracked by Wall St. Rank hold ALT as of Q4 2020.

Arrowstreet Capital reported no remaining Altimmune position as of Q4 2020 after selling out during the quarter.
Arrowstreet Capital sold 15,000 Altimmune shares in Q4 2020, an estimated $198K.
Arrowstreet Capital first reported a position in Altimmune in Q1 2017 and held it in 5 quarters.
Arrowstreet Capital's Altimmune position peaked at $530K in Q1 2017.
89 funds tracked by Wall St. Rank held Altimmune as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.